Scarica l'app Stockscreener
16.39
0.18%
-0.15
Precedente Chiudi:
$16.24
Aprire:
$16.22
Volume 24 ore:
11,016
Relative Volume:
0.13
Capitalizzazione di mercato:
$547.21M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-16.83%
1M Prestazione:
-32.15%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$16.11
$16.53
Intervallo di 1 settimana:
$15.31
$20.45
Portata 52W:
$15.31
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Nome
Mbx Biosciences Inc
Settore
Industria
Telefono
(317) 989-3100
Indirizzo
12406 HORESHAM STREET, CARMEL
Confronta MBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| MBX | 16.44 | 547.21M | 0 | 0 | 0 | 0.00 |
| VRTX | 447.58 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.92 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mbx Biosciences Inc Borsa (MBX) Ultime notizie
MBX Biosciences (NYSE:MBX) Shares Gap DownHere's What Happened - MarketBeat
MBX Biosciences completes phase 1 trial of diabetes drug - Investing.com India
MBX Biosciences (NYSE:MBX) Shares Gap UpWhat's Next? - MarketBeat
MBX Biosciences Announces Last Subject Last Visit in Phase - GlobeNewswire
MBX Biosciences (NYSE:MBX) Reaches New 12-Month Low – Here’s Why - Defense World
MBX Biosciences (NYSE:MBX) Sets New 1-Year LowWhat's Next? - MarketBeat
MBX Biosciences: Decent Potential For Lead Indication, But Need More Data (NASDAQ:MBX) - Seeking Alpha
MBX Biosciences Reports Q3 2024 Financial Progress - MSN
Wellington Management Group LLP Acquires New Stake in MBX Biosci - GuruFocus.com
MBX Biosciences Inc. (MBX) Quarterly 10-Q Report - Quartzy
MBX Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
MBX Biosciences Secures $251M in IPO, Advances Clinical Pipeline with Strong Cash Position | MBX Stock News - StockTitan
MBX Biosciences (NYSE:MBX) Shares Up 8.2%Time to Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Up 6.8%Should You Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Sets New 52-Week LowTime to Sell? - MarketBeat
MBX Biosciences to Participate in Upcoming November Investor Conferences - The Manila Times
MBX Biosciences (NYSE:MBX) Shares Down 4.5%Here's What Happened - MarketBeat
MBX Biosciences sets IPO terms with plans to raise up to $136 million - MSN
MBX Biosciences, Inc.'s (NYSE:MBX) Quiet Period To End on October 23rd - MarketBeat
MBX Biosciences, Inc.’s Quiet Period Set To Expire on October 23rd (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Stock Price Down 4%Here's Why - MarketBeat
MBX Bio drops despite bullish views on Street - MSN
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - BNN Bloomberg
MBX Biosciences (NYSE:MBX) Shares Up 4.6%Here's What Happened - MarketBeat
MBX Biosciences earns Buy rating at three investment firms - MSN
MBX Bio stock drops despite bullish initiations (NASDAQ:MBX) - Seeking Alpha
Guggenheim bullish on MBX Biosciences stock, driven by MBX 2109 potential - Investing.com Canada
MBX Biosciences outlook solid with JPMorgan's overweight rating, eyes key catalysts in next 12 months - Investing.com India
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements - Investing.com India
MBX Biosciences earns Buy rating at three investment firms By Investing.com - Investing.com Canada
Guggenheim Begins Coverage on MBX Biosciences (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Now Covered by JPMorgan Chase & Co. - MarketBeat
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements By Investing.com - Investing.com South Africa
MBX Biosciences (NYSE:MBX) Stock Price Down 3.5%Should You Sell? - MarketBeat
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ - GlobeNewswire
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting - Yahoo Finance
MBX Biosciences (NYSE:MBX) Trading Down 4.1% - MarketBeat
MacroGenics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMGNX - PR Newswire
HighVista Strategies LLC Lowers Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Lelezard
330 Shares in Monolithic Power Systems, Inc. (NASDAQ:MPWR) Bought by Brighton Jones LLC - Defense World
Mbx Biosciences Inc Azioni (MBX) Dati Finanziari
Non sono disponibili dati finanziari per Mbx Biosciences Inc (MBX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):